Lupin has received approval from the US health regulator to market its generic Doxycycline hyclate tablets, used for treatment of infections, in the American market. The company has received final approval from the United States Food and Drug Administration for its tablets in the strength of 100 mg. According to June 2017 data, Doxycycline hyclate tablets USP in 100 mg strength had US sales of $149.9 million, the drug firm said.